LENZ Therapeutics Inc (LENZ)

Currency in USD
8.94
-0.13(-1.43%)
Closed·
8.97+0.03(+0.34%)
·
Trading near 52-week Low
LENZ is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.579.18
52 wk Range
8.5750.40
Key Statistics
Prev. Close
9.07
Open
8.91
Day's Range
8.57-9.18
52 wk Range
8.57-50.4
Volume
2.04M
Average Vol. (3m)
1.05M
1-Year Change
-66.3023%
Book Value / Share
9.09
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LENZ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
44.43
Upside
+396.96%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

LENZ Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

LENZ Therapeutics Inc Earnings Call Summary for Q4/2025

  • LENZ reported $1.6M Q4 revenue from VIZZ presbyopia treatment launch; holds $292.3M cash with zero debt but posted $35.9M net loss.
  • Operating expenses surged 43% sequentially to $40M; net loss per share widened to $1.16 from $0.46 year-over-year in Q4.
  • Stock plunged 12% post-earnings to $10.5, near 52-week low, down 73% over six months despite analyst targets of $35-$62.
  • Company projects Q1 2026 VIZZ sales exceeding 45,000 boxes; plans to allocate 75-80% of expenses to sales/marketing with 90% gross margin.
  • Executives emphasized strong liquidity position to fund growth while facing investor concerns over sustained losses and elevated cash burn rate.
Last Updated: 03/24/2026, 09:58 AM
Read Full Transcript

Compare LENZ to Peers and Sector

Metrics to compare
LENZ
Peers
Sector
Relationship
P/E Ratio
−3.4x−8.2x−0.4x
PEG Ratio
0.160.240.00
Price / Book
1.0x1.9x2.6x
Price / LTM Sales
14.7x8.0x3.1x
Upside (Analyst Target)
-67.7%57.3%
Fair Value Upside
Unlock2.8%8.0%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 44.43
(+396.96% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citi
Buy26.00+190.83%52.00MaintainMar 25, 2026
H.C. Wainwright
Buy56.00+526.40%-MaintainMar 25, 2026
BofA Securities
Buy29.00+224.38%35.00MaintainMar 24, 2026
Piper Sandler
Buy39.00+336.24%62.00MaintainMar 24, 2026
William Blair
Buy---MaintainMar 10, 2026

Earnings

Latest Release
Mar 24, 2026
EPS / Forecast
-1.16 / -0.76
Revenue / Forecast
1.59M / --
EPS Revisions
Last 90 days

LENZ Income Statement

People Also Watch

204.75
ONTO
-7.37%
603.17
SNDK
-11.02%
9.440
ONDS
-8.44%
98.27
CRCL
-5.38%
450.46
AXON
-2.11%

FAQ

What Is the LENZ Therapeutics (LENZ) Stock Price Today?

The LENZ Therapeutics stock price today is 8.94 USD.

What Stock Exchange Does LENZ Therapeutics Trade On?

LENZ Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for LENZ Therapeutics?

The stock symbol for LENZ Therapeutics is "LENZ."

What Is the LENZ Therapeutics Market Cap?

As of today, LENZ Therapeutics market cap is 280.31M USD.

What Is LENZ Therapeutics's Earnings Per Share (TTM)?

The LENZ Therapeutics EPS (TTM) is -2.85.

From a Technical Analysis Perspective, Is LENZ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has LENZ Therapeutics Stock Split?

LENZ Therapeutics has split 1 times.

How Many Employees Does LENZ Therapeutics Have?

LENZ Therapeutics has 152 employees.

What is the current trading status of LENZ Therapeutics (LENZ)?

As of Mar 27, 2026, LENZ Therapeutics (LENZ) is trading at a price of 8.94 USD, with a previous close of 9.07 USD. The stock has fluctuated within a day range of 8.57 USD to 9.18 USD, while its 52-week range spans from 8.57 USD to 50.40 USD.

What Is LENZ Therapeutics (LENZ) Price Target According to Analysts?

The average 12-month price target for LENZ Therapeutics is 44.43 USD, with a high estimate of 62 USD and a low estimate of 20 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +396.96% Upside potential.

What Is the LENZ Premarket Price?

LENZ's last pre-market stock price is 8.91 USD. The pre-market share volume is 6,330.00, and the stock has decreased by -0.16, or -1.76%.

What Is the LENZ After Hours Price?

LENZ's last after hours stock price is 8.97 USD, the stock has decreased by 0.03, or 0.34%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.